Compare Abbott Laboratories (ABT) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Abbott Laboratories trades at $95.38 (market cap $166.94B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.02. The key difference: Abbott Laboratories pays a 2.63% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals.
| ABT | VNQI | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | — |
52-Week High | $136.62 | $50.76 |
52-Week Low | $82.57 | $43.26 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.50, up 0.38% with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF offers international real estate diversification with a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent news highlights its cost advantage over competitors and institutional buying interest from Eagle Bay Advisors, which increased its stake by 95.7% in Q4 2025.
VNQI presents a compelling opportunity for yield-seeking investors seeking global real estate exposure at low cost, with recovery potential as global transaction volumes are expected to rise over 10% in 2026. Key risks include currency fluctuations, international economic volatility, and interest rate sensitivity. The ETF's valuation appears reasonable at 11.9x P/E and 0.9x P/B according to Seeking Alpha analysis from May 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
